Ascletis Announces First Participants Dosed In A U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, And Semaglutide For The Treatment Of Obesity
May 20 (Reuters) - Ascletis Pharma Inc 1672.HK:
ASCLETIS ANNOUNCES FIRST PARTICIPANTS DOSED IN A U.S. CLINICAL STUDY COMBINING ADIPOSE-TARGETED, ONCE-MONTHLY INJECTABLE SMALL MOLECULE THRΒ AGONIST, ASC47, AND SEMAGLUTIDE FOR THE TREATMENT OF OBESITY
ASCLETIS PHARMA INC - TOPLINE DATA FROM STUDY EXPECTED IN Q4 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.